Home » Trials » SLCTR/2025/033
Development of a mobile-based mindfulness intervention and study of its effectiveness in improving maternal psychological wellbeing
-
SLCTR Registration Number
SLCTR/2025/033
Date of Registration
The date of last modification
Aug 24, 2025
Scientific Title of Trial
Development of a mobile-based mindfulness intervention and study of its effectiveness in improving maternal psychological wellbeing
Public Title of Trial
Development and evaluation of a mobile-based mindfulness intervention for improving maternal mental health and neonatal outcomes: a randomized controlled trial with waitlisted control group
Disease or Health Condition(s) Studied
Maternal Mental Health
Scientific Acronym
None
Public Acronym
None
Brief title
None
Universal Trial Number
U1111-1324-5290
Any other number(s) assigned to the trial and issuing authority
ERC/2023/82 (Ethics Review Committee, Faculty of Medicine, Rajarata University of Sri Lanka
What is the research question being addressed?
Are smartphone applications delivering mindfulness-based meditation interventions effective in enhancing mental well-being among pregnant and postpartum women, and what are its effects on neonatal health outcomes?
Type of study
Interventional
Study design
Allocation
Randomized controlled trial
Masking
Masking not used
Control
Standard therapy/practice
Assignment
Parallel
Purpose
Supportive care
Study Phase
Not Applicable
Intervention(s) planned
Study Setting: The study will be conducted in maternal hospitals and antenatal clinics, where eligible participants will be recruited during their routine antenatal visits. Following recruitment and baseline data collection, participants will continue the intervention independently at home, accessing it through a mobile application developed specifically for this study.
Method of Randomization: A simple randomization method will be employed. Every other participant who consents to participate will be allocated to the experimental (intervention) group, with the remaining participants allocated to the waitlisted control group. Unit of Randomization: The unit of randomization will be the individual pregnant woman. Method of Sequence Generation: Randomization will follow a manual allocation sequence, where every other eligible and consenting participant will be assigned to the experimental group as they are enrolled. Method of Allocation Concealment: There will be no allocation concealment in this study. Participants will be fully informed about their group allocation at the time of enrolment and consent.
Intervention Description: The intervention will consist of a mobile-based mindfulness therapy, specifically designed and delivered through a mobile application developed for this study. The intervention is based on mindfulness-based meditation practices and delivered digitally through the mobile application. The intervention will be carried out on an individual basis, with participants engaging mindfulness meditation sessions independently at their own convenience. Participants will access and engage with the intervention at home or any preferred location using their personal mobile devices. Participants in the intervention group will be instructed to complete daily mindfulness meditation sessions, each lasting 5–10 minutes, for a period of 8 consecutive weeks. Multiple sessions will be available each day through the application, with participants encouraged to engage in at least one session per day for the 8-week period. The intervention is self-administered through the mobile application. No external facilitator or therapist will deliver the sessions directly. However, the participants will be free to contact the research team for any question or concern
Control Group Description: Participants in the waitlisted control group will not receive the intervention during the initial 8-week study period. However, after completing the follow-up assessments at the end of 8 weeks, control group participants will be offered access to the same mobile-based mindfulness intervention if they wish to participate. The control group will receive no intervention during the study period. After 8 weeks, they will be offered access to the intervention, to be followed at their own convenience, identical to the experimental group.
Standard Care for Both Groups: During the study, both the intervention and waitlisted control groups will continue to receive standard antenatal care provided by the respective maternal hospitals and clinics. This includes routine antenatal check-ups, health education, and obstetric care as per hospital guidelines. The study intervention is an adjunct to standard care and does not replace any existing clinical or psychological support services. To reduce biases and to reduce risk for the participants, any mother who is under a standard psychological therapy will be excluded from the study.
Inclusion criteria
• Pregnant mothers from the 6th and 7th months of the pregnancy (at the commencement of data collection), • Have access to a smart device • The pregnant mothers are required to have a considerable fluency to understand English or Sinhalese to be included into the study.
Exclusion criteria
• Participants who are under any form of a therapy support for mental health problems • Further, mothers who have a history of suicidal thoughts or attempts (high risk) will be excluded from the study
Primary outcome(s)
1.
Level of depression, anxiety, and stress measured by Depression, Anxiety and Stress Scale-21 (DASS-21) |
[ Assessed at the baseline, after 8 weeks from the baseline, 2 months and 4 months after the delivery of the baby. ] |
2.
Level of psychological wellbeing using Psychological Wellbeing Scale developed by Ryff and Keyes (1995 |
[ Assessed at the baseline, after 8 weeks from the baseline, 2 months and 4 months after the delivery of the baby. ] |
3.
Level of mindfulness using Mindful Attention Awareness Scale (MAAS) |
[ Assessed at the baseline, after 8 weeks from the baseline, 2 months and 4 months after the delivery of the baby. ] |
Secondary outcome(s)
1.
Baby’s birth recordings (APGAR score, birth weight, term of delivery, head size) |
[ Birth ] |
Target number/sample size
128 (64 in each arm)
Countries of recruitment
Sri Lanka
Anticipated start date
2025-09-01
Anticipated end date
2026-04-01
Date of first enrollment
Date of study completion
Recruitment status
Pending
Funding source
Self funded
Regulatory approvals
N/A
Status
Approved
Date of Approval
2024-10-08
Approval number
ERC/2023/82
Details of Ethics Review Committee
Name: | Ethics Review Committee of General Sir John Kotelawala Defence University |
Institutional Address: | Ethics Review Committee of the Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka. |
Telephone: | +94 (0)25 2053633 |
Email: | erc@med.rjt.ac.lk |
Contact person for Scientific Queries/Principal Investigator
Lakshani Jayasinha
Principal Investigator
NSBM Green University, Mahenwatta, Pitipana, Homagama
0115445236
0716928274
lakshani.j@nsbm.ac.lk
Contact Person for Public Queries
Prof. Nishantha Kumarasinghe
Professor of Anatomy, Head of the Department - Pre Clinical Sciences General Sir John Kotelawala Defence University
General Sir John Kotelawala Defence University,
Kandawala Estate,
Rathmalana,
Sri Lanka
+94718002880
nishantha@kdu.ac.lk
Primary study sponsor/organization
General Sir John Kotelawala Defence University
General Sir John Kotelawala Defence University,
Kandawala Estate,
Rathmalana,
Sri Lanka
0112 635 268
https://kdu.ac.lk/
Do the investigators plan to share identified individual clinical trial participant-level data (IPD)?
No
IPD sharing plan description
NA
Study protocol available
No
Protocol version and date
Not Available
Protocol URL
Not Available
Results summary available
No
Date of posting results
Date of study completion
Final sample size
Date of first publication
Link to results
Brief summary of results